Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Might Need To Split, Divest To Stay Competitive – Analysts

This article was originally published in The Tan Sheet

Executive Summary

P&G could benefit from splitting into two businesses, divesting its premium fragrances or pulling out of core personal care product categories, experts suggest. Financial services firm UBS says, “While P&G is stepping up its spending, cutting costs and accelerating new product launches – so are its competitors.”

You may also be interested in...



In Brief

While the so-called fiscal cliff has been avoided, sequestration still looms for FDA and other government agencies. The European Chemicals Agency updates its list of Substances of Very High Concern.

P&G Shareholders Push For More Power Over Board Membership

With more power to shake up P&G’s board, shareholders could ultimately have a greater hand in changes to company management. Activist investor William Ackman – whose firm Pershing Square Capital owns roughly a 1% stake in the firm – is rumored to be pushing to replace P&G CEO Bob McDonald.

P&G Plans More Price Cuts In 2013, Defends Savings Plan

Procter & Gamble will slash prices on some products in the short term to halt U.S. market share erosion in categories where competitors did not previously raise prices. On the firm’s Q4 earnings call, executives defended their bullish growth and savings projections.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel